Corbin Capital Partners, L.P. Arbutus Biopharma Corp Transaction History
Corbin Capital Partners, L.P.
- $65.7 Million
- Q3 2024
A detailed history of Corbin Capital Partners, L.P. transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Corbin Capital Partners, L.P. holds 853,304 shares of ABUS stock, worth $3 Million. This represents 5.0% of its overall portfolio holdings.
Number of Shares
853,304
Previous 853,304
-0.0%
Holding current value
$3 Million
Previous $2.64 Million
24.62%
% of portfolio
5.0%
Previous 7.38%
Shares
1 transactions
Others Institutions Holding ABUS
# of Institutions
156Shares Held
99.6MCall Options Held
2.31MPut Options Held
525K-
Morgan Stanley New York, NY21.7MShares$76.2 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY12.9MShares$45.2 Million26.34% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$40.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$31.3 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.39MShares$29.4 Million10.86% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $526M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...